

Synthesis and pharmacological evaluation of *N*-substituted 6,7-benzomorphans



National Institute
on Drug Abuse

Madhurima Das¹, Agnieszka Sulima¹, Thomas E. Prisinzano²,
Dan Luo², Arthur E. Jacobson¹, Kenner C. Rice¹




National Institute
on Alcohol Abuse
and Alcoholism

¹ Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, 9800 Medical Center Drive, Bethesda ; ²Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, Kentucky


Introduction

The structure of morphine can be made smaller and simpler and still retain its activity. One such class of less complex compounds are the 6,7-benzomorphans. Some of them were found to be much more potent than morphine and were thought to have fewer side effects.^{1,2}



Structural relationship between morphine, benzomorphans and phenylmorphans


Various studies have shown that the nature of the substituent at the secondary nitrogen of normetazocine (**1**) affects the biological response of the molecule. Metazocine (**2**) was found to be just as potent as morphine. Replacing the methyl group with a saturated alkyl chain like ethyl, propyl and butyl resulted in loss of analgesia. However, phenazocine (**3**) in which the methyl group is replaced by a phenethyl substituent was found to be 20 times more potent than morphine.³



In this work, a series of (-)-*N*-phenethyl-6,7-benzomorphans have been synthesized with electron withdrawing or donating substituents on the aromatic ring of the *N*-phenethyl moiety. The compounds were examined for agonist activity in a cAMP assay.


Synthesis

Optical resolution




Optical resolution of normetazocine⁴

Optical purity of the product was determined by NMR using (*R*)-methylbenzylisocyanate as a chiral derivatizing agent.



Comparison of NMR after adding (*R*)-methylbenzylisocyanate to enriched and pure product


N-alkylation with substituted phenethyl bromides



Synthesis of substituted *N*-phenethyl-6,7-benzomorphans

Optically resolved (-)-**1** was then subjected to *N*-alkylation with various substituted phenethyl bromides to give a series of substituted *N*-phenethyl analogs of 6,7-benzomorphans.

μ opioid receptor (MOR) activity



MOR activity of **4a-f** in cAMP assay

4a-f were tested for MOR activity in a cAMP assay. All analogs were found to be highly potent, fully efficacious μ opioid receptor (MOR) agonists with the exception of the *ortho* trifluoromethyl substituted analog (**4d**) that had potency similar to that of morphine. The *para* bromo substituted analog (**4e**) was 7 times more potent than morphine.

Conclusion

- A series of substituted *N*-phenethyl analogs **4a-f** were prepared.
- Substituents at the *para* position led to more potent compounds.
- Substituents at the *ortho* position led to lower potency.
- Synthesis of other *ortho* and *meta* substituted analogs is currently underway.

REFERENCES

- 1.) May, E. L.; Murphy, J. G., *J. Org. Chem.* **1955**, *20* (9), 1197–1201.
- 2.) May, E. L. *J. Org. Chem.* **1956**, *21*, 899-901.
- 3.) Weijland, J., Orhovats, P. D., Sullivan, A. P., Purdue, G., Heath, F. K., Pfister, K., *J. Chem. Soc.* **1956**, *78*, 2342.
- 4.) Boulanger, W. A. *Synthetic Communications* **1999**, *29*, 2201-2210.

ACKNOWLEDGMENTS

The work of the Drug Design and Synthesis Section, Molecular Targets and Medication Discovery Branch, NIDA, & NIAAA, was supported by the NIH Intramural Research Programs of the National Institute on Drug Abuse (NIDA) and the National Institute of Alcohol Abuse and Alcoholism (NIAAA). We thank Dr. Thomas Prisinzano and Dr. Dan Luo at the University of Kentucky for *in vitro* testing.